Stanford-StartX Fund has supported a $4m round for Imprimed, which is working on precision cancer treatments for dogs.

Willow Biosciences is the result of a three-way merger between University of Calgary spinout Epimeron, BioCan Technologies and CSE-listed Makena Resources.

The biopharmaceutical company, formerly known as Pronutria Biosciences and backed by Nestlé Health Science, has filed for an $86.3m offering following $172m of funding.

Pfizer is the largest shareholder of Alzheimer's drug developer Cortexyme, which has filed to raise up to $86.3m in its initial public offering.

Stanford spinout Cardinal Analytx has raised $20.6m out of a targeted $29.3m, adding to a $6.1m series A round backed by Stanford-StartX Fund in 2017.

Asklepios BioPharmaceutical, based on work by UNC Chapel Hill professors Jude Samulski and Xiao Xiao, has secured $235m in funding co-led by TPG Capital and Vida Ventures.

PureTech Health and Mitsubishi Tanabe Pharma took part in the Merck Group-led series A round, which will fund work developing Sonde's voice-based medical monitoring technology.

Kingmed Diagnostics was among the investors in the $44.7m round, the proceeds of which will fund development of Creative Biosciences' cancer diagnostics kits.

Sidewalk Labs spinoff Cityblock raised the cash in an EmblemHealth and Echo Health Ventures-backed round that took its overall funding above $85m.

Sequoia China Capital and Highlight Capital co-led the GNI Group-backed cancer drug developer's series A round.